Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer

详细信息    查看全文

• 作者：Nathan Touati^a ; ^{nathan.touati@eortc.be} ; Konstantinos Tryfonidis^b ; ^{Konstantinos.tryfonidis@eortc.be} ; Franco Caramia^c ; ^{Franco.Caramia@petermac.org} ; Hervé ; Bonnefoi^d ; ^{H.Bonnefoi@bordeaux.unicancer.fr} ; David Cameron^e ; ^{D.Cameron@ed.ac.uk} ; Leen Slaets^a ; ^{leen.slaets@eortc.be} ; Belinda S. Parker^f ; ^{Belinda.Parker@Iatrobe.edu.uk} ; Sherene Loi^c ; ^{sherene.loi@petermac.org}
• 关键词：IRF7 signature ; Severe infection ; Breast cancer ; Bone metastases ; Immune response ; Neo-adjuvant chemotherapy
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：95-102
• 全文大小：712 K
• 卷排序：72

文摘

Innate immunity has shown to prevent metastatic potential in pre-clinical models. Infection can activate an innate immune response regulated by interferon regulatory factor 7 (IRF7). Clinical data of the European Organisation for Research and Treatment of Cancer 10994/BIG 1-00 phase III trial were analysed to evaluate this hypothesis. High expression of the IRF7 gene signature was significantly associated with reduced bone relapse. The efficacy of adjuvant bisphosphonate/denosumab could be influenced by tumour IRF7 status.